Study drug TRE-515 for advanced solid tumors using PET scans
Part of Cancer clinical trials.
This Phase 1 trial tests how safe TRE-515 is, what dose can be used, and how the drug moves through the body, including using PET scans. It’s for adults with advanced solid cancers that have stopped responding to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed solid cancer (by biopsy or cell test).
- Your cancer is advanced and no longer responds to standard treatment, and you’re not a candidate for curative therapy.
- You have tumors that can be measured on scans, or—if prostate/ovarian—your tumor marker is rising (PSA or CA-125).
- You’re age 18 or older and able to sign informed consent.
- Your body can handle the study tests: you can swallow capsules, tolerate IV blood draws, and get PET scans (or the site has PET access).
- Your recent labs and overall strength are adequate, and you’ve recovered from side effects of prior cancer treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether an investigational PET scan tracer is safe and tolerable when used for PET imaging in people with certain solid cancers. It mainly looks at side effects and how well the scan can be done, not whether it treats cancer.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial tests a new imaging agent (18F-TRX) to see if it can better detect cancer spread in people with advanced solid tumors. It is designed for patients with specific cancers like high-grade brain tumors, advanced kidney cancer, or prostate cancer that has stopped responding to hormone therapy.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
This early-stage study tests a new drug (HEC169096) in people with advanced solid tumors that cannot be removed by surgery. It focuses on tumors with specific RET gene changes, aiming to control or shrink the cancer and improve outcomes.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.